Cargando…
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis
INTRODUCTION: The design of clinical trials of interventions aimed at reducing mortality in patients with severe sepsis assumes that the relative treatment effect of the intervention is independent of the patients' risk for death. We reviewed published data from phase III clinical studies of se...
Autores principales: | Macias, William L, Nelson, David R, Williams, Mark, Garg, Rekha, Janes, Jonathan, Sashegyi, Andreas |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1414006/ https://www.ncbi.nlm.nih.gov/pubmed/16280057 http://dx.doi.org/10.1186/cc3795 |
Ejemplares similares
-
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
por: Williams, Mark D, et al.
Publicado: (2006) -
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
por: Laterre, Pierre-François, et al.
Publicado: (2008) -
Severe protein C deficiency association with organ dysfunction and mortality in patients with severe sepsis
por: Vail, M, et al.
Publicado: (2007) -
Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007) -
Lack of clinically evident signs of organ failure affects ED treatment of patients with severe sepsis
por: Kakebeeke, Dirkjan, et al.
Publicado: (2013)